Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IP · 1 trial · 1 indication
To evaluate the effect of food on the single-dose pharmacokinetics (PK) of NX-5948 in healthy subjects.
To evaluate the effect of food on the single-dose pharmacokinetics (PK) of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the PK of NX-5948 following 2 doses of NX-5948 given 12 hours apart in healthy subjects.
To evaluate the PK of NX-5948 following 2 doses of NX-5948 given 12 hours apart in healthy subjects.
To evaluate the PK of NX-5948 following 2 doses of NX-5948 given 12 hours apart in healthy subjects.
| Arm | Type | Description |
|---|---|---|
| Part 1: Sequence 1 (Treatment A, B, C) | EXPERIMENTAL | Period 1: NX-5948 or placebo administered under fasted conditions Period 2: NX-5948 or placebo administered under fed conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4 |
| Part 1: Sequence 2 (Treatment B, A, C) | EXPERIMENTAL | Period 1: NX-5948 or placebo administered under fed conditions Period 2: NX-5948 or placebo administered under fasted conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4 |
| Part 2: NX-5948 PK | EXPERIMENTAL | Experimental: Part 2: NX-5948 PK NX-5948 or placebo administered 2 doses given 12 hours apart under fasted conditions |
| Name | Type | Description |
|---|---|---|
| IP | DRUG | NX-5948 oral |
| Matching Placebo | DRUG | Fluconazole |
Inclusion Criteria: Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study: * Healthy, adult, male, 18-55 years of age * Subjects must follow protocol-specified contraception guidance as described in the protocol. * Continuous non-smoker who has...
IP is a small molecule drug candidate developed by Nurix Therapeutics, Inc. under the ticker NRIX. It is in Phase 1 clinical development. Its therapeutic indications have not been disclosed. The program has been studied in a completed Phase 1 trial involving healthy adult volunteers.
IP is being developed by Nurix Therapeutics, Inc., which trades under the ticker NRIX. Nurix is the sponsor of the clinical program for this small molecule drug candidate.
IP is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program has not been approved by the FDA and remains investigational.
IP has been evaluated in one completed Phase 1 trial, NCT06593457, titled A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects. The trial enrolled 32 participants in the United States and was conducted in healthy adult male volunteers.
Yes. IP is also known as NX-5948. The completed Phase 1 trial NCT06593457 refers to the drug as NX-5948, while the program is listed under the name IP. Both names refer to the same small molecule drug candidate from Nurix Therapeutics.
The completed Phase 1 trial NCT06593457 evaluated food effects, drug-drug interactions, and pharmacokinetics of IP, also known as NX-5948. It was a controlled, randomized, double-blind study that enrolled 32 healthy adult male volunteers at sites in the United States.